MicroTransponder Secures $65 Million to Enhance Vivistim Adoption for Chronic Stroke Recovery

Whats Happening:

MicroTransponder, Inc. has secured a $65 million Series F financing round to enhance the adoption of its FDA-approved Vivistim Paired VNS System for chronic stroke recovery. The funding was led by US Venture Partners and includes a syndicate of current and new investors. Vivistim is the first FDA-approved intervention clinically proven to help chronic ischemic stroke survivors regain significantly more upper extremity function.

Key Moves:

• MicroTransponder secures $65 million in Series F financing

• Funding to enhance adoption of FDA-approved Vivistim Paired VNS System

• Expansion into 20% of Joint Commission Comprehensive Stroke Centers

By The Numbers:

• Vivistim helps stroke survivors regain 2-3 times more upper extremity function

• 20% of Joint Commission Comprehensive Stroke Centers have adopted Vivistim

• 50% of Becker's 2024 100 Great Neuro and Spine Programs use Vivistim

Key Quotes:

• "We're excited by the combination of commercial excellence and the overwhelmingly positive clinical outcomes that show material improvements in stroke survivors' quality of life with Paired VNS Therapy." - Casey Tansey, USVP general partner

• "We've helped build new programs that support our goal of changing the standard of care for stroke treatment across the US, renewing hope for stroke survivors and their caregivers." - Richard Foust, MicroTransponder's CEO

Bottom Line:

MicroTransponder's $65 million Series F funding round signifies strong investor confidence in its Vivistim Paired VNS System for chronic stroke recovery. The company's rapid adoption in leading stroke centers and positive clinical outcomes position it to potentially transform the standard of care for stroke treatment across the US, offering new hope for stroke survivors and their caregivers.

Read Full Article